Atara Biotherapeutics vs Humacyte
ATRA and HUMA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ATRA and HUMA compare
Humacyte is the larger company, worth 2.0 times as much as Atara Biotherapeutics ($164M against $82.6M).
Humacyte grew revenue faster over the last twelve months (52.5% versus −97.4% for Atara Biotherapeutics).
Atara Biotherapeutics keeps more of each dollar of sales as profit, with a net margin of −369% compared with −3955% at Humacyte.
Atara Biotherapeutics scores higher on the StockData Score (7 against 2 for Humacyte), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ATRA | HUMA |
|---|---|---|
| Size and price | ||
| Market cap | $82.6M | $164M |
| Share price | $8.23 | $0.592 |
| Change, 1 year | −33.1% | −56.2% |
| Change, 5 years | −98.2% | −94.6% |
| Beta (5Y) | 1.65 | 2.06 |
| Employees | 14 | 184 |
| StockData Score | ||
| Total score | 7 (better) | 2 |
| Valuation score | 0 | 0 |
| Growth score | 1 | 1 |
| Performance score | 1 (better) | 0 |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 20.8× (better) | 68.6× |
| P/B | – | 9.1× |
| FCF yield | – | −53.9% |
| Growth | ||
| Revenue growth (TTM) | −97.4% | 52.5% (better) |
| Net income growth (TTM) | −162% | – |
| Profitability | ||
| Gross margin | – | −475% |
| Operating margin | −344% (better) | −4603% |
| Net margin | −369% (better) | −3955% |
| FCF margin | – | −3697% |
| Return on equity | – | −1424% |
| Financial health | ||
| Interest coverage | – | −11.0× |
| Current ratio | 1.72 | 3.34 (better) |
| Altman Z-score | −153.99 | −10.29 (better) |
| Piotroski F-score | 5 (better) | 4 |
| Dividends and buybacks | ||
| Buyback yield | −10.4% | – |
| Shareholder yield | −10.4% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 44.5% | 26.4% |
| Held by insiders | 55.5% | 8.0% |
| Insider net buying, 12 months | $2.0M (better) | $7.4K |
| Short interest, % of float | 6.6% | 11.0% |
Go deeper
- ATRA stock overview
- ATRA income statement
- ATRA valuation and score
- HUMA stock overview
- HUMA income statement
- HUMA valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.